Lilly climbs, Novo falls as obesity drug battle intensifies
Eli Lilly's stock rose as its injectable obesity drugs outperformed expectations, while Novo Nordisk faced a decline following a trial setback and lower-than-expected sales for its Wegovy pill. Both companies are competing aggressively in the high-growth GLP-1 drug market.
Why it matters
The competition between these two pharmaceutical giants is reshaping the obesity treatment market and significantly impacting investor sentiment in the healthcare sector.
A research disappointment and a miss on Wegovy pill sales hurt Novo, while Lilly’s injectable franchise once again surpassed analyst expectations.
Novo’s Ozempic, sold as Wegovy for obesity, was the first in the GLP-1 class of drugs to become a household name. But the company has steadily lost market share to Lilly, whose stock value has soared past the trillion-dollar mark.
The Danish drugmaker is trying to regain its footing with a new, higher-dose version of Wegovy and the oral formulation of the medicine. It has also touted the potential for CagriSema , a next-generation weekly injectable currently under Food and Drug Administration review. But CagriSema has delivered mixed results in studies , including the setback in the so-called Reimagine 4 trial announced Tuesday.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in